

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/015950

## A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl<sup>7</sup> A61K45/00, 31/7088, 38/17, 48/00, A61P25/00, 25/28, 43/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl<sup>7</sup> A61K45/00, 31/7088, 38/17, 48/00, A61P25/00, 25/28, 43/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAPLUS (STN), MEDLINE (STN), BIOSIS (STN), EMBASE (STN)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	WO 2003/070895 A2 (RIBOZYME PHARMACEUTICALS, INC.), 28 August, 2003 (28.08.03), Particularly, Claims; examples & EP 1423404 A2 & US 2003/190335 A1 & GB 23296155 A	1, 2 3-11
X A	JP 2003-289881 A (Director of Chubu National Hospital), 14 October, 2003 (14.10.03), Particularly, Claims; examples & WO 2003/012141 A1	1, 2 3-11

☒ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search  
14 January, 2005 (14.01.05)

Date of mailing of the international search report  
01 February, 2005 (01.02.05)

Name and mailing address of the ISA/  
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/015950

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	WO 2003/024485 A1 (Ono Pharmaceutical Co., Ltd.), 27 March, 2003 (27.03.03), Particularly, Claims; examples (Family: none)	1,2 3-11
X A	WO 2003/057165 A2 (THE POCKEFELLER UNIVERSITY), 17 July, 2003 (17.07.03), Particularly, Claims; examples & US 2004/0028673 A1 & EP 1469810 A2	1,2 3-11
X A	JP 2003-525947 A (MERCK SHARP & DOHME LTD.), 02 September, 2003 (02.09.03), Particularly, Claims; examples & WO 2001/066564 A2 & EP 1263774 A1 & US 2003/0055005 A1	1,2 3-11
X A	JP 2002-322198 A (Pfizer Products Inc.), 08 November, 2002 (08.11.02), Particularly, Claims; page 2, left column, lines 13 to 21; examples & EP 1233021 A2 & US 2002/0115616 A1	1,2 3-11
X A	JP 2002-173448 A (Sumitomo Pharmaceuticals Co., Ltd.), 21 June, 2002 (21.06.02), Particularly, Claims; examples (Family: none)	1,2 3-11
A	WO 2002/052007 A1 (LOCOMOGENE, INC.), 04 July, 2002 (04.07.02), (Family: none)	1-11

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/JP2004/015950

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

The inventions according to claims 1 to 11 relate to a medicinal composition containing a substance inhibiting secretase activity. In contrast, the inventions according to claims 12, 13 and 16 relate to a method of inhibiting secretase activity characterized by comprising promoting the sensitivity of a secretase inhibitor, and the inventions according to claims 14 to 16 relate to a method of inhibiting secretase activity characterized by comprising binding synoviolin to Herp. However, both of the method of inhibiting secretase activity characterized by comprising promoting the sensitivity of a secretase inhibitor and the method of inhibiting secretase activity characterized by comprising binding synoviolin (continued to extra sheet)

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1 to 11

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/JP2004/015950

Continuation of Box No.III of continuation of first sheet(2)

to Herp cannot be considered as methods specifically applied to the production of the a medicinal composition containing a substance inhibiting secretase activity. Thus, there is no matter common to them which is seemingly a special technical feature in the meaning within the second sentence of PCT Rule 13.2 and no technical relationship in the meaning within PCT Rule 13 can be found out among these inventions differing from each other. Such being the case, it does not appear that there is a technical relationship between these groups of inventions involving one or more of the same or corresponding special technical features and, therefore, they are not considered as relating to a group of inventions so linked as to form a single general inventive concept.

## &lt;Subject of search&gt;

Claims 1 to 7 relate to a medicinal composition containing a substance defined as a desired property "a substance inhibiting secretase activity" as the active ingredient. Claims 5 to 7 relate to a composition containing, as the active ingredient, siRNA or shRNA being "siRNA or shRNA to a gene encoding synoviolin" and defined by a desired property "a synoviolin expression inhibitor". Although claims 1 to 7 involve any compounds having such a property, it is recognized that only part of the claimed compounds are supported by the description in the meaning within PCT Article 6 and disclosed therein in the meaning within PCT Article 5.

Although the common technical knowledge at the point of the application is taken into consideration, the scope of compounds having the property "a substance inhibiting secretase activity" cannot be specified. Thus, claims 1 to 7 do not comply with the requirement of clearness under PCT Article 6 too.

Such being the case, the search was made on the relation ship among the treatment of Alzheimer's disease, the inhibition of secretase activity and synoviolin, and remedies for Alzheimer's disease comprising the compounds as specified in claims 8 and 9 as the active ingredient. Complete search was made on claims 8 and 9.

BEST AVAILABLE COPY